Bharat Vaswani1, Palanki Satya Dattatreya2, Sagar Bhagat3, Saiprasad Patil4, Hanmant Barkate4. 1. Consultant Oncologist and Hematologist, Yashoda Cancer Institute, Secunderabad, India. 2. Consultant Oncologist and Hematologist, Omega Hospital, Hyderabad, India. 3. Medical Services, IF, Glenmark Pharmaceutical limited, B D Sawant Road, Andheri [East], Mumbai, 400099, India. sagar.bhagat@glenmarkpharma.com. 4. Medical Services, IF, Glenmark Pharmaceutical limited, B D Sawant Road, Andheri [East], Mumbai, 400099, India.
Abstract
BACKGROUND: Chemotherapy induced nausea- vomiting (CINV) is considered as the most common, feared and most troublesome side effect of chemotherapy. NEPA (NEtupitant 300 mg + PAlonosetron 0.50 mg) is the first commercially available oral fixed-dose combination (FDC) of two active antiemetic agents in India. The present study was planned to evaluate the effectiveness of NEPA in the real world setting of India. METHODS: This was a multicentric retrospective study conducted in two centers in India. The data of all chemonaive patients, who were prescribed NEPA was analyzed. Effectiveness i.e. complete response and complete protection in controlling overall, acute and delayed phase was analyzed. RESULTS: A total of 329 patients were enrolled in the study. 260 received highly emetogenic chemotherapy (HEC) regimen and 69 received moderately emetogenic chemotherapy (MEC) regimen. Among all the enrolled patients, complete response in acute, delayed and overall phase was 93, 85.71 and 85.41% respectively; and completed protection was 88.44, 81.76 and 80.54% respectively. Those who received HEC regimen, the completed response and complete protection in overall phase was 84.61 and 79.61% respectively and those who received MEC regimen the completed response and complete control in overall phase was 84.05 and 84.05% respectively. CONCLUSION: A single oral dose of NEPA targeting dual pathways showed effective control of nausea-vomiting in patients on the HEC and MEC regimens and had good control over nausea-vomiting in acute, delayed and overall phase of nausea-vomiting.
BACKGROUND: Chemotherapy induced nausea- vomiting (CINV) is considered as the most common, feared and most troublesome side effect of chemotherapy. NEPA (NEtupitant 300 mg + PAlonosetron 0.50 mg) is the first commercially available oral fixed-dose combination (FDC) of two active antiemetic agents in India. The present study was planned to evaluate the effectiveness of NEPA in the real world setting of India. METHODS: This was a multicentric retrospective study conducted in two centers in India. The data of all chemonaive patients, who were prescribed NEPA was analyzed. Effectiveness i.e. complete response and complete protection in controlling overall, acute and delayed phase was analyzed. RESULTS: A total of 329 patients were enrolled in the study. 260 received highly emetogenic chemotherapy (HEC) regimen and 69 received moderately emetogenic chemotherapy (MEC) regimen. Among all the enrolled patients, complete response in acute, delayed and overall phase was 93, 85.71 and 85.41% respectively; and completed protection was 88.44, 81.76 and 80.54% respectively. Those who received HEC regimen, the completed response and complete protection in overall phase was 84.61 and 79.61% respectively and those who received MEC regimen the completed response and complete control in overall phase was 84.05 and 84.05% respectively. CONCLUSION: A single oral dose of NEPA targeting dual pathways showed effective control of nausea-vomiting in patients on the HEC and MEC regimens and had good control over nausea-vomiting in acute, delayed and overall phase of nausea-vomiting.
Authors: Ruey Kuen Hsieh; Alexandre Chan; Hoon-Kyo Kim; Shiying Yu; Jong Gwang Kim; Myung-Ah Lee; Johan Dalén; Hun Jung; Yan Ping Liu; Thomas A Burke; Dorothy M K Keefe Journal: Support Care Cancer Date: 2014-08-14 Impact factor: 3.603
Authors: Paul J Hesketh; Mark G Kris; Ethan Basch; Kari Bohlke; Sally Y Barbour; Rebecca Anne Clark-Snow; Michael A Danso; Kristopher Dennis; L Lee Dupuis; Stacie B Dusetzina; Cathy Eng; Petra C Feyer; Karin Jordan; Kimberly Noonan; Dee Sparacio; Mark R Somerfield; Gary H Lyman Journal: J Clin Oncol Date: 2017-07-31 Impact factor: 44.544
Authors: F Roila; A Molassiotis; J Herrstedt; M Aapro; R J Gralla; E Bruera; R A Clark-Snow; L L Dupuis; L H Einhorn; P Feyer; P J Hesketh; K Jordan; I Olver; B L Rapoport; J Roscoe; C H Ruhlmann; D Walsh; D Warr; M van der Wetering Journal: Ann Oncol Date: 2016-09 Impact factor: 32.976
Authors: Michelle C Janelsins; Mohamedtaki A Tejani; Charles Kamen; Anita R Peoples; Karen M Mustian; Gary R Morrow Journal: Expert Opin Pharmacother Date: 2013-04 Impact factor: 3.889
Authors: G Dranitsaris; A Molassiotis; M Clemons; E Roeland; L Schwartzberg; P Dielenseger; K Jordan; A Young; M Aapro Journal: Ann Oncol Date: 2017-06-01 Impact factor: 32.976
Authors: Matti Aapro; Meinolf Karthaus; Lee Schwartzberg; Igor Bondarenko; Tomasz Sarosiek; Cristina Oprean; Servando Cardona-Huerta; Vincent Hansen; Giorgia Rossi; Giada Rizzi; Maria Elisa Borroni; Hope Rugo Journal: Support Care Cancer Date: 2016-11-24 Impact factor: 3.603